Real‐world persistence of multiple sclerosis disease‐modifying therapies.

MLA

Tallantyre, Emma C., et al. “Real‐world Persistence of Multiple Sclerosis Disease‐modifying Therapies.” European Journal of Neurology, vol. 31, no. 7, July 2024, pp. 1–10. EBSCOhost, https://doi.org/10.1111/ene.16289.

APA

Tallantyre, E. C., Dobson, R., Froud, J. L. J., St, J. F. A., Anderson, V. M., Arun, T., Buckley, L., Evangelou, N., Ford, H. L., Galea, I., George, S., Gray, O. M., Hibbert, A. M., Hu, M., Hughes, S. E., Ingram, G., Kalra, S., Lim, C. E., Mathews, J. T. M., & McDonnell, G. V. (2024). Real‐world persistence of multiple sclerosis disease‐modifying therapies. European Journal of Neurology, 31(7), 1–10. https://doi.org/10.1111/ene.16289

Chicago

Tallantyre, Emma C., Ruth Dobson, Joseph L. J. Froud, John, Frederika A. St, Valerie M. Anderson, Tarunya Arun, Lauren Buckley, et al. 2024. “Real‐world Persistence of Multiple Sclerosis Disease‐modifying Therapies.” European Journal of Neurology 31 (7): 1–10. doi:10.1111/ene.16289.